Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 30 versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 30 versus VISIPAQUE 320.
CONRAY 30 vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, providing vascular and organ opacification. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
Intravenous: 50-300 mL of a 30% solution (150-900 mg iodine/kg) as a single dose for contrast enhancement. Dosing depends on procedure and patient weight.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Renal (90-100% unchanged via glomerular filtration within 24 hours); minimal biliary/fecal (<1%)
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent